Enzymatica AB · OMXSTO:ENZY

Enzymatica AB — Investor Presentation (2021)

32 slides from Enzymatica AB's investor presentation, 2021

  1. Slide 1: Company presentation 2021

    Company presentation 2021 Enzymatica AB (publ)

  2. Slide 2: Contents

    Contents This is Enzymatica...................................................................................................3 The year in figures...................................................................................................4 Important events during the year....................

  3. Slide 3: This is Enzymatica

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Operations This is Enzymatica Business concept Enzymatica develops and sells medical devices to treat infection-related diseases in the upper Enzymat

  4. Slide 4: The year in figures

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Operations The year in figures Sales trend (SEK m) 120 Key figures (SEK thousand) 2021 2020 2019 2018 2017 Net sales, SEK thousand 57,243 111,245 61,

  5. Slide 5: Important events during the year

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Operations Important events during the year Q1 Q2 Q3 Q4 » Enzymatica restructured the organization » The Japanese Patent Office granted » The Chinese

  6. Slide 6: How Enzymatica was affected by Covid-19

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Operations How Enzymatica was affected by Covid-19 The coronavirus pandemic has had a very strong impact on Enzymatica’s sales and earnings in 2021.

  7. Slide 7: Enzymatica – heading for the future

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Comments from the CEO Enzymatica – heading for the future In less than 15 years, Enzymatica has gone from a creative commercial opportunities for eac

  8. Slide 8: Three reasons to invest in Enzymatica

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Targets & strategy Three reasons to invest in Enzymatica Throughout the challenging times of the past two years, Enzymatica continued to work accordi

  9. Slide 9: A scalable business model

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Targets & strategy A scalable business model Flexibility and scalability are hallmarks of the Enzymatica business model. By balancing its own experti

  10. Slide 10: Continued three-dimensional expansion

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Targets & strategy Continued three-dimensional expansion For many years, Enzymatica’s growth strategy has been based on three pillars: Strengthening

  11. Slide 11: Strong partners all over the world

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Targets & strategy Strong partners all over the world In recent years, Enzymatica has built strong relationships with some of the world’s leading pla

  12. Slide 12: Financial targets for Enzymatica

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Targets & strategy Financial targets for Enzymatica On November 2, 2021, the Board adopted financial targets for Enzymatica. At the end of 2026, the

  13. Slide 13: The share and shareholding

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION The share The share and shareholding At year-end Enzymatica had 8,420 shareholders – a decrease of about 12 percent compared with 2020. The share pri

  14. Slide 14: Number of shareholders

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION The share The share and shareholding Enzymatica’s ten largest shareholders December 30, 2021 Name Number of shares Percentage of capital and votes (%

  15. Slide 15: Share capital and share price

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION The share Share capital and share price Increase in number of Total number Change in Total Registered Transaction shares of shares share capital shar

  16. Slide 16: 16 | Enzymatica company presentation 2021

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION 16 | Enzymatica company presentation 2021

  17. Slide 17: ColdZyme treats the cause of colds

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Product & market ColdZyme treats the cause of colds The ColdZyme® barrier consists of two ingredients that together provide effective protection GLYC

  18. Slide 18: Global market with great potential

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Product & market Global market with great potential The global market for over-the-counter cold and allergy products is estimated at USD 37 billion a

  19. Slide 19: Situation in local markets

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Product & market Situation in local markets ColdZyme was sold at the end of 2021 on 36 markets worldwide, either under its own brand or under the bra

  20. Slide 20: New MDR regulation entails extensive changes

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Product & market New MDR regulation entails extensive changes May 26, 2021 was an historic day for EU medical device legislation. The Medical Device

  21. Slide 21: Global patent portfolio protects rights

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Product & market Global patent portfolio protects rights Enzymatica has extensive patent protection for ColdZyme and continuously works to expand thi

  22. Slide 22: 22 | Enzymatica company presentation 2021

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION 22 | Enzymatica company presentation 2021

  23. Slide 23: Research on barrier technology potential

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Production & development Research on barrier technology potential The purpose of research and development at Enzymatica is to investigate the possibi

  24. Slide 24: Building out production for global expansion

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Production & development Building out production for global expansion During a year with lower-than-expected demand, the focus has been on expanding

  25. Slide 25: Ongoing efforts to ensure high quality

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Production & development Ongoing efforts to ensure high quality Enzymatica’s systematic quality management system encompasses the entire value chain,

  26. Slide 26: Sustainable development with a focus on people

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Production & development Sustainable development with a focus on people Enzymatica shall be a good stakeholder in the community and take responsibili

  27. Slide 27: 27 | Enzymatica company presentation 2021

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION 27 | Enzymatica company presentation 2021

  28. Slide 28: Comments from the Chairman of the Board

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Corporate governance Comments from the Chairman of the Board Foundation laid for expansion There is no doubt that 2021 was a challenging year for We

  29. Slide 29: Corporate governance report

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Corporate governance Corporate governance report Governance of Enzymatica takes place through the General Meeting, the Board of Directors, the CEO an

  30. Slide 30: Corporate governance: Auditor, CEO and senior management

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Corporate governance Auditor General Meeting on October 18, 2021 resolved to approve an Deloitte was re-elected as the company's auditor at the 2021

  31. Slide 31: Financial Overview

    CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Financial Overview (SEK thousand) 2021 2020 2019 2018 2017 Net sales, SEK thousand 57,243 111,245 61,306 52,560 59,446 Capitalized development costs,

  32. Slide 32: Enzymatica AB contact details

    Enzymatica’s unique barrier technology protects people’s health by creating a shield against viruses, bacteria and other microorganisms that cause colds and infections. We focus on global expansion through innovation and partnerships. ENZYMATICA AB (PUBL) IDEON SCIENCE PARK, SE-223 70 LUND, SWEDEN.

Enzymatica — Investor Presentation (2021) on 6ix